Novartis Ag

Chiron Corporation

Glaxosmithkline Biologicals Sa

Sclavo Spa

Aima-derivati S.p.a.

Francesco Norelli

Paolo Costantino

Francesco Berti

Roberto Olivieri

Aldo Giannozzi

Silvia Fontani

Concetta Cicala

Giulia Bazzocchi

Giovanni Averani

Rino Rappuoli

Silvana Arrighi

Maria G Borri

Costante Ceccarini

Stefano Viti

Sandro D'Ascenzi

Cinzia Bellucci

Massimo Bigio

Enzo Bucci

Concetta Maria Cicala

This application relates to methods for the purification of saccharide antigen-carrier protein conjugates. In particular, the invention provides a method for purifying saccharide antigen-carrier protein conjugates from free carrier protein, such as CRM1 97, using hydroxyapatite. The invention further relates to methods of preparing vaccines, using this method.

Conjugate purification

This invention is in the field of bacterial cultures and specifically relates to the optimization of culture conditions to improve the production of bacterial capsular polysaccharides fromstrains in fed batch culture and to novel purification methods suitable for production scale purification of bacterial capsular polysaccharides fromstrains resulting in higher levels of purity than previously obtained for production scale.

[object Object]

Saccharide-protein conjugates having a new type of linker are described. The conjugates comprising the new linker are prepared from modified saccharides comprising a moiety of the formula (I): -A-N(R)-L-M wherein: A is a bond, &#x2014;C(O)&#x2014; or &#x2014;OC(O)&#x2014;; R1 is selected from H or C-Calkyl; L is a C-Calkylene group; and M is a masked aldehyde group. The new linker is especially useful for preparing conjugates ofserogroup A saccharide. Conjugates having this new linker have improved immunogenicity compared to other types of conjugates.

Modified saccharides, conjugates thereof, and their manufacture

Fermentation processes for cultivating streptococci and purification processes for obtaining CPS therefrom

The present invention provides conjugate compounds comprising at least one heat shock protein or portion thereof including at least one immunostimulatory domain and at least one capsular oligosaccharide or polysaccharide of a pathogenic bacteria. The compound comprises oligosaccharides of the Meningococci C (MenC) group and a heat shock protein selected from BCG GroE1-type 65 kDa hsp (hspR65), recombinant DnaK-type 70 kDa hsp (hspR70) and a heat shock protein from . The invention also provides processes for producing conjugate compounds, pharmaceutical compositions comprising conjugate compounds, therapeutic compositions comprising conjugate compounds, and methods of inducing an immune response.

Conjugates formed from heat shock proteins and oligo-or polysaccharides

A combined vaccine for bacterial meningitis comprises Hib and MenC oligosaccharide conjugates.

Combined meningitis vaccine

A description is given of a process for the purification of factor IX, factor X, and factor II from human plasma or fractions thereof, wherein a solution containing prothrombin complex factors is purified by repeated ion exchange chromatographic separations followed by adsorption chromatography on metal ions.

Process for the isolation of highly purified factors IX, X and II from

Growing community of inventors

Siena, Italy

Francesco Norelli